Search Results - "Krejčí, Marta"

P1294: REAL‐WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT‐ELIGIBLE MULTIPLE MYELOMA PATIENTS by Popková, Tereza, Pour, Ludek, Spicka, Ivan, Radocha, Jakub, Jungova, Alexandra, Minarik, Jiri, Pavlíček, Petr, Jelínek, Tomas, Krejčí, Marta, Straub, Jan, Maisnar, Vladimir, Dekojová, Tereza, Pika, Tomáš, Soukup, Jan, Pospíšilová, Lenka, Hájek, Roman

Get full text

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study by Raje, Noopur, Terpos, Evangelos, Willenbacher, Wolfgang, Shimizu, Kazuyuki, García-Sanz, Ramón, Durie, Brian, Legieć, Wojciech, Krejčí, Marta, Laribi, Kamel, Zhu, Li, Cheng, Paul, Warner, Douglas, Roodman, G David

“…Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal-related events (spinal cord…”
Get full text

Lenalidomide proved effective in multisystem Langerhans cell histiocytosis by Szturz, Petr, Adam, Zdeněk, Rehák, Zdeněk, Koukalová, Renata, Slaisová, Radka, Stehlíková, Olga, Chovancová, Jana, Klabusay, Martin, Krejčí, Marta, Pour, Luděk, Hájek, Roman, Mayer, Jiří

Get more information

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies by Radocha, Jakub, Maisnar, Vladimír, Pour, Luděk, Špička, Ivan, Minařík, Jiři, Szeligová, Lenka, Pavlíček, Petr, Jungová, Alexandra, Krejčí, Marta, Pika, Tomáš, Straub, Jan, Brožová, Lucie, Stejskal, Lukáš, Heindorfer, Adriana, Jindra, Pavel, Kessler, Petr, Mikula, Peter, Sýkora, Michal, Wróbel, Marek, Jarkovský, Jiří, Hájek, Roman

“…This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised…”
Get full text

IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen by Adam, Zdenek, Krejčí, Marta, Pour, Luděk, Feit, Josef, Büchler, Tomáš, Hájek, Roman

“…Summary Monoclonal gammopathy-associated IgA pemphigus is a debilitating skin disorder with inconsistent response to treatment. A 61-year-old woman with IgA…”
Get full text

Cytokine analysis in a patient with relapsing Kikuchi-Fujimoto disease by Szturz, Petr, Adam, Zden k, Chovancová, Jana, Stehlíková, Olga, Klabusay, Martin, Feit, Josef, K en, Leoš, Fojtík, Zden k, Krej í, Marta, Pour, Lud k, Hájek, Roman, Mayer, Ji í

Get full text

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse by Pour, Ludek, Sevcikova, Sabina, Greslikova, Henrieta, Kupska, Renata, Majkova, Petra, Zahradova, Lenka, Sandecka, Viera, Adam, Zdenek, Krejci, Marta, Kuglik, Petr, Hajek, Roman

“…Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of…”
Get full text

Lenalidomide: a new treatment option for Castleman disease by Szturz, Petr, Adam, Zden k, Chovancová, Jana, Stehlíková, Olga, Klabusay, Martin, ehák, Zden k, Koukalová, Renata, Krej í, Marta, Pour, Lud k, Zahradová, Lenka, Hájek, Roman, Mayer, Ji í

Get full text

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes by de Swart, Louise, Reiniers, Chloé, Bagguley, Timothy, van Marrewijk, Corine, Bowen, David, Hellström-Lindberg, Eva, Tatic, Aurelia, Symeonidis, Argiris, Huls, Gerwin, Cermak, Jaroslav, van de Loosdrecht, Arjan A, Garelius, Hege, Culligan, Dominic, Macheta, Mac, Spanoudakis, Michail, Panagiotidis, Panagiotis, Krejci, Marta, Blijlevens, Nicole, Langemeijer, Saskia, Droste, Jackie, Swinkels, Dorine W, Smith, Alex, de Witte, Theo

“…Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients with myelodysplastic syndromes. We hypothesized that…”
Get full text

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease by Stork, Martin, Ondrouskova, Eva, Bohunova, Michaela, Boichuk, Ivanna, Fric, Dominik, Adam, Zdenek, Krejci, Marta, Sandecka, Viera, Knechtova, Zdenka, Radova, Lenka, Jelinkova, Zuzana, Adlerova, Tatana, Krticka, Milan, Nekuda, Vladimir, Borsky, Marek, Sevcikova, Sabina, Jarosova, Marie, Pour, Ludek

Get full text

Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy by Minarik, Jiri, Pavlicek, Petr, Pour, Ludek, Pika, Tomas, Maisnar, Vladimir, Spicka, Ivan, Jarkovsky, Jiri, Krejci, Marta, Bacovsky, Jaroslav, Radocha, Jakub, Straub, Jan, Kessler, Petr, Wrobel, Marek, Walterova, Lenka, Sykora, Michal, Obernauerova, Jarmila, Brozova, Lucie, Gregora, Evzen, Adamova, Dagmar, Gumulec, Jaromir, Adam, Zdenek, Scudla, Vlastimil, Hajek, Roman

“…Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis…”
Get full text

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma by Besse, Lenka, Sedlarikova, Lenka, Kryukov, Fedor, Nekvindova, Jana, Radova, Lenka, Slaby, Ondrej, Kuglik, Petr, Almasi, Martina, Penka, Miroslav, Krejci, Marta, Adam, Zdenek, Pour, Ludek, Sevcikova, Sabina, Hajek, Roman

“…Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In…”
Get full text

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance by Sandecká, Viera, Hájek, Roman, Pour, Luděk, Špička, Ivan, Ščudla, Vlastimil, Gregora, Evžen, Radocha, Jakub, Walterová, Lenka, Kessler, Petr, Zahradová, Lenka, Adamová, Dagmar, Valentova, Kamila, Vonke, Ivan, Obernauerová, Jarmila, Starostka, David, Wróbel, Marek, Brožová, Lucie, Jarkovský, Jiří, Mikulášová, Aneta, Říhová, Lucie, Ševčíková, Sabina, Straub, Ján, Minařík, Jiří, Adam, Zdeněk, Krejčí, Marta, Král, Zdeněk, Maisnar, Vladimír

“…Introduction Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion. Patients and methods…”
Get full text

Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse by Radocha, Jakub, Pour, Luděk, Pika, Tomáš, Maisnar, Vladimír, Špička, Ivan, Gregora, Evžen, Krejčí, Marta, Minařík, Jiří, Machálková, Kateřina, Straub, Jan, Pavlíček, Petr, Hájek, Roman, Žák, Pavel

“…Introduction The normalization of free light chain ratio (FLCr) has been introduced as a marker of stringent complete remission (CR) of multiple myeloma (MM)…”
Get full text

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party by Auner, Holger W., Iacobelli, Simona, Sbianchi, Giulia, Knol-Bout, Cora, Blaise, Didier, Russell, Nigel H., Apperley, Jane F., Pohlreich, David, Browne, Paul V., Kobbe, Guido, Isaksson, Cecilia, Lenhoff, Stig, Scheid, Christof, Touzeau, Cyrille, Jantunen, Esa, Anagnostopoulos, Achilles, Yakoub-Agha, Ibrahim, Tanase, Alina, Schaap, Nicolaas, Wiktor-Jedrzejczak, Wieslaw, Krejci, Marta, Schönland, Stefan O., Morris, Curly, Garderet, Laurent, Kröger, Nicolaus

“…Melphalan at a dose of 200 mg/m 2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140…”
Get full text

Histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Comparison of recent WHO classification published 2017 and classification of Histiocyte Society published 2016 by Král, Zdeněk, Adam, Zdeněk, Ježová, Marta, Pour, Luděk, Krejčí, Marta

“…The histiocytoses are rare disorders characterized by the accumulation of cells thought to be derived from dendritic cells or macrophages. Their clinical…”
Get more information

Combination of serum microRNA‐320a and microRNA‐320b as a marker for Waldenström macroglobulinemia by Kubiczkova Besse, Lenka, Sedlarikova, Lenka, Kryukov, Fedor, Nekvindova, Jana, Radova, Lenka, Almasi, Martina, Pelcova, Jana, Minarik, Jiri, Pika, Tomas, Pikalova, Zuzana, Scudla, Vlastimil, Krejci, Marta, Adam, Zdenek, Pour, Ludek, Hajek, Roman, Sevcikova, Sabina

Get full text

Salvage lenalidomide in four rare oncological diseases by Szturz, Petr, Adam, Zdenek, Rehak, Zdenek, Koukalova, Renata, Kren, Leos, Moulis, Mojmír, Krejcí, Marta, Mayer, Jiri

“…In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as…”
Get full text

MicroRNAs in urine are not biomarkers of multiple myeloma by Sedlarikova, Lenka, Besse, Lenka, Novosadova, Sona, Kubaczkova, Veronika, Radova, Lenka, Stanik, Michal, Krejci, Marta, Hajek, Roman, sevcikova, Sabina

“…In this study, we aimed to identify microRNA from urine of multiple myeloma patients that could serve as a biomarker for the disease. Analysis of urine samples…”
Get full text

Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment by Szturz, Petr, Adam, Zden k, Vašk, Vladimír, Feit, Josef, Krej í, Marta, Pour, Lud k, Hájek, Roman, Mayer, Ji í

Get full text